NR3C2 and acute myeloid leukemia: Myelodysplasia-related AML substantially increased from 22% (158/734) AML-MRC to 28% (208/746) AML-MR in WHO 2022 (Supplementary Fig. S4A; 122/208 former AML-MRC, 49/208 former AML-NOS, 37/208 former AML-RUNX1).